CD3+/CD4+ % refers to the percentage of T-helper cells (a subtype of white blood cells) among all T-lymphocytes (T cells) in your blood. This marker is often measured as part of an immune panel using flow cytometry, especially in contexts involving immune system monitoring, such as HIV, autoimmune conditions, or immunodeficiency assessments.

Understanding the Components

• CD3+ T cells: Represent all mature T lymphocytes, a key part of the adaptive immune system.

• CD4+ T cells: A subset of CD3+ cells, often called T-helper cells, which coordinate immune responses by signaling other immune cells.

• CD3+/CD4+ %: The percentage of total T cells that are CD4+. This gives insight into the relative balance of helper T cells within the T cell population.

CD3+/CD4+, Abs stands for the absolute count of CD4+ T-helper cells within the total population of CD3+ T cells in the blood. This marker measures the exact number of helper T cells per microliter (μL) of blood, rather than just their percentage. It is a key indicator of immune system function, especially in the context of infections like HIV, immune deficiencies, and chronic inflammatory conditions.

CD3+/CD8+ % refers to the percentage of cytotoxic T cells (CD8+) among all T-lymphocytes (CD3+ cells) in your blood. This immune marker is measured using flow cytometry and is commonly included in T-cell subset panels to evaluate immune system status.

Understanding the Components

• CD3+ T cells: Represent all mature T lymphocytes, which are essential for adaptive immunity.

• CD8+ T cells: A subset of CD3+ cells, often called cytotoxic T cells, that directly kill infected or abnormal cells (like virus-infected cells or cancer cells).

• CD3+/CD8+ %: Indicates the proportion of cytotoxic T cells among total T cells, helping assess immune activation, suppression, or imbalance.

CD3+/CD8+, Abs refers to the absolute count of cytotoxic T cells (CD8+) within the population of total T cells (CD3+) in your blood. This test measures the number of CD8+ T cells per microliter (μL) of blood and is a critical marker for evaluating immune function, especially in viral infections, immune disorders, and after immune-modulating treatments.

Understanding the Components

• CD3+ T cells: Represent all mature T lymphocytes—key players in the adaptive immune system.

• CD8+ T cells: A subset of CD3+ T cells, known as cytotoxic T cells, that target and destroy virus-infected, cancerous, or otherwise abnormal cells.

• “Abs” (Absolute): Indicates the actual number of CD3+/CD8+ cells per microliter (μL) of blood, not just the percentage.

Why Is the Absolute CD3+/CD8+ Count Important?

The CD8+ absolute count provides important insight into:

• Immune activation during viral infections (e.g., HIV, CMV, EBV)

• T-cell immune surveillance and response

• Immune suppression or recovery following chemotherapy, transplant, or immunodeficiency

• Chronic inflammation or autoimmune disease activity

This test looks at the ratio of two important types of white blood cells in your blood.

Lymphocytes are a type of white blood cell in your immune system. This test looks at two of them, CD4 and CD8.

CD4 cells lead the fight against infections. CD8 cells can kill cancer cells and other invaders.

This test looks at the ratio of two important types of white blood cells in your blood.

Lymphocytes are a type of white blood cell in your immune system. This test looks at two of them, CD4 and CD8.

CD4 cells lead the fight against infections. CD8 cells can kill cancer cells and other invaders.

The CD4/CD8 ratio is a critical marker of immune system health. It measures the balance between CD4+ T-helper cells and CD8+ cytotoxic T cells, two major subtypes of T lymphocytes. These cells play complementary roles in immune defense:

• CD4+ T-helper cells coordinate immune responses by activating other immune cells.
• CD8+ cytotoxic T cells directly attack infected or cancerous cells.

The ratio is calculated by dividing the absolute count of CD4+ cells by that of CD8+ cells, and it provides insight into the state of immune regulation, activation, and balance.

This test looks at the ratio of two important types of white blood cells in your blood.

Lymphocytes are a type of white blood cell in your immune system. This test looks at two of them, CD4 and CD8.

CD4 cells lead the fight against infections. CD8 cells can kill cancer cells and other invaders.

The CD4/CD8 ratio (CD3+) is an important marker that reflects the balance between two major subsets of T lymphocytes—CD4+ helper T cells and CD8+ cytotoxic T cells—within the total T-cell population (CD3+). This ratio is a key indicator of immune system health, especially in conditions involving immune deficiency, chronic infections, inflammation, and immune reconstitution.

Understanding the Components

• CD3+ T cells: Represent all mature T lymphocytes. Both CD4+ and CD8+ T cells fall under this category.

• CD4+ T cells: Also known as helper T cells, they coordinate immune responses by signaling other immune cells.

• CD8+ T cells: Also known as cytotoxic T cells, they destroy infected, damaged, or cancerous cells.

• CD4/CD8 Ratio (CD3+): The ratio of helper T cells to cytotoxic T cells within the CD3+ T-cell population.

The CD4 cells are Helper T-cells expressing both CD3 and CD4.

CD4 T-cells levels are a criterion for categorizing HIV-related clinical conditions by CDC's classification system for HIV infection. The measurement of CD4 T-cell levels has been used to establish decision points for initiating P. jirovecii prophylaxis, antiviral therapy and to monitor the efficacy of treatment. The Public Health Service (PHS) has recommended that CD4 T-cell levels be monitored every 3 to 6 months in all HIV-infected persons.

During HIV infection, antiviral therapy is often initiated when the absolute CD4 count drops below 500 cells/µL. When the absolute CD4 count drops below 200 cells/µL, therapeutic prophylaxis against PCP and other opportunistic infections may be initiated. When the absolute CD4 count drops below 100 cells/µL, prophylaxis against Mycobacterium avium complex is recommended.

CD56 is an adhesion molecule mediating homophilic and heterophilic adhesion in neurons, natural killer cells, and a small subset of CD4- and CD8-positive T cells. It is expressed in tumors with neuroendocrine differentiation (small cell lung carcinoma and neural-derived tumors) or natural killer cell lineage (subset of lymphomas). In normal small intestine, the ganglion cells in the muscle wall and nerves will show strong staining. Scattered lymphocytes may also be positive.

CD56 is an adhesion molecule mediating homophilic and heterophilic adhesion in neurons, natural killer cells, and a small subset of CD4- and CD8-positive T cells. It is expressed in tumors with neuroendocrine differentiation (small cell lung carcinoma and neural-derived tumors) or natural killer cell lineage (subset of lymphomas). In normal small intestine, the ganglion cells in the muscle wall and nerves will show strong staining. Scattered lymphocytes may also be positive.

CD56+CD3- (absolute) cells are crucial in the immune system, primarily acting as natural killer (NK) cells. Their unique combination of CD56 positivity and CD3 negativity makes them essential for defending against pathogens and cancer cells. These cells are pivotal in diagnosing and managing immune-related conditions and cancers, highlighting their role in personalized medicine.

CD56+CD3- % is a key immunological marker identifying natural killer (NK) cells, essential in innate immunity. Elevated levels can indicate an active immune response or certain malignancies, while decreased levels may suggest impaired immunity, as seen in HIV/AIDS or post-chemotherapy. This parameter is crucial in transplant immunology for monitoring immune reconstitution and in assessing the effectiveness of immunotherapies, particularly in cancer treatments. CD56+CD3- % thus plays a significant role in diagnosing, monitoring, and treating immune and hematological disorders.

The CD57 test is offered in some clinical laboratories and is being used by some health practitioners to evaluate and follow patients diagnosed with chronic Lyme disease.

The CD57 test is offered in some clinical laboratories and is being used by some health practitioners to evaluate and follow patients diagnosed with chronic Lyme disease.

The "CD8-CD57+ Lymphocytes (Absolute)" marker on an HNK1 (CD57) panel from Labcorp represents a specific measurement of immune cells within your blood, quantified absolutely rather than as a percentage of total lymphocytes. This test focuses on a subset of natural killer (NK) cells and T lymphocytes, both critical components of your immune system's arsenal against infections and malignancies. These CD8-CD57+ cells, often referred to in the context of natural killer cell function due to their ability to directly attack and kill virus-infected cells or tumor cells without the need for prior activation, are unique. When you have a higher or lower than normal absolute count of these cells, it can be indicative of various health conditions. For example, a low absolute count of CD8-CD57+ lymphocytes is often observed in patients suffering from chronic conditions like Lyme disease, indicating a weakened immune response possibly due to the prolonged battle against the infection. On the other hand, understanding the high end of these counts is less straightforward but could suggest an active immune response to an infection or stress. This marker is particularly useful for clinicians in the context of diagnosing and managing chronic infectious diseases, as it provides insight into the state of the immune system's natural killer cell function. However, interpreting the results of this marker should always be done within the broader context of a patient's overall health, symptoms, and other laboratory findings to ensure a comprehensive understanding of their immune status.

The CD57 test is offered in some clinical laboratories and is being used by some health practitioners to evaluate and follow patients diagnosed with chronic Lyme disease.